February 7, 2014
Protease Inhibitors Make a First Splash
The first wave of new HCV drugs arrived in the form of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), which were approved in the U.S. in 2011 for the treatment of HCV genotype 1. They have not yet been approved specifically for HIV-coinfected patients, however -- and Cox suggested that their day in the sun may be setting.
In clinical trials, boceprevir and telaprevir have both been shown to dramatically increase HCV treatment success rates in therapy-naive, HIV-coinfected patients. But they still must be taken with interferon, and both drugs have been found to exacerbate the adverse effects seen among patients taking interferon-based therapies. Between those sobering data and extensive drug-interaction concerns with HIV medications, "it's not easy to take these medications," Cox said.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|Which Hepatitis C Treatment to Start in 2016|
|This Week in HIV Research: Antibody Suppresses HIV; Investigational Drug BMS-986001; and Quality of Care on Mortality|
|This Week in HIV Research: Smoking Associated With Poor HIV Outcomes; How Gay Men Decide on Condomless Sex; and More|
|High Liver Enzymes Signal Serious Disease in HIV-Positive Individuals Without Hepatitis|
|This Week in HIV Research: Tenofovir Resistance Alarmingly Common; Ongoing HIV Replication Replenishes Reservoirs; and More|
|Dolutegravir: A Powerful Drug Entering Different Research Paths|